Dual Plasmepsin-Targeting Antimalarial Agents Disrupt Multiple Stages of the Malaria Parasite Life CyclePaola Favuzza, Alan F. Cowman, Lianyun Zhao et al.|Cell Host & Microbe|2020Cited by 167
Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect micePhillip Pymm, Wai‐Hong Tham, Amy Adair et al.|Proceedings of the National Academy of Sciences|2021Cited by 165
Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domainAdam K. Wheatley, Wai‐Hong Tham, Phillip Pymm et al.|Cell Reports|2021Cited by 80
Basis for drug selectivity of plasmepsin IX and X inhibition in Plasmodium falciparum and vivaxAnthony N. Hodder, Alan F. Cowman, Janni Christensen et al.|Structure|2022Cited by 32
Basis for drug selectivity of plasmepsin IX and X inhibition for Plasmodium falciparum and vivaxAnthony N. Hodder, Alan F. Cowman, S.W. Scally et al.|Research Square|2021Cited by 1